A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM)
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2017
At a glance
- Drugs AZD 8601 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 14 Sep 2017 Status changed from active, no longer recruiting to completed, according to a Moderna Therapeutics media release.
- 07 Aug 2017 Planned End Date changed from 29 Dec 2017 to 2 Jan 2018.
- 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.